WHO ICTRP trial
MERCURY study
JPRN-jRCT1080223554 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT1080223554 |
|---|---|
| Public title | MERCURY study |
| Scientific title | A 24-month, phase IV, open-label, single arm, multicenter, prospective, observational study assessing the efficacy and safety of subsequent treatment after initiation of intravitreal injection of ranibizumab 0.5 mg in diabetic macular edema patients with impaired visual acuity through individualized… |
| Primary sponsor | Novartis Pharma K.K. |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Observational |
| Phase | 4 |
| Countries | Japan |
| Conditions | Diabetic Macular Edema (DME) |
| Interventions | investigational material(s) Generic name etc : Lucentis INN of investigational material : Ranibizumab Therapeutic category code : 131 Agents for ophthalmic use Dosage and Administration for Investigational material : 0.5 mg ranibizumab… |
| Registration date | Jul 6, 2017 |
| Target size | 200 |
| Secondary IDs | JapicCTI-173610 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: